Gilead Sciences Inc. advised its shareholders Friday to reject a “mini-tender” offer by TRC Capital Corp. to buy up to 3 million shares.
That amount would equal about 0.37 percent of the outstanding shares of Gilead (NASDAQ: GILD), the Foster City-based developer of HIV, respiratory and other types of drugs.
No comments:
Post a Comment